Novavax (NVAX) Capital Leases (2012 - 2026)

Novavax's Capital Leases history runs 10 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Capital Leases fell 96.41% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 96.41% YoY), while the FY2025 annual figure was $2.1 million, down 96.11% from the prior year.
• Capital Leases was $1.9 million for Q1 2026 at Novavax, down from $2.1 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $55.9 million in Q4 2023 to a low of $1.9 million in Q1 2026.
• Historically, Capital Leases has averaged $37.5 million across 5 years, with a median of $52.4 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Capital Leases jumped 79.02% in 2023, then sank 96.41% in 2026.
• A 5-year view of Capital Leases shows it stood at $31.2 million in 2022, then surged by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024, then sank by 96.11% to $2.1 million in 2025, then slipped by 8.8% to $1.9 million in 2026.
• The last three Capital Leases figures came in at $1.9 million (Q1 2026), $2.1 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.